Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
128.50
-0.88 (-0.68%)
At close: Jun 30, 2026, 4:00 PM EDT
128.00
-0.50 (-0.39%)
After-hours: Jun 30, 2026, 7:57 PM EDT
Revenue
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 |
Keytruda/Keytruda Qlex Revenue | 8.03B | |||||||||||||||||||||||
Keytruda/Keytruda Qlex Revenue Growth | 11.51% | |||||||||||||||||||||||
Gardasil/Gardasil 9 Revenue | 1.07B | |||||||||||||||||||||||
Gardasil/Gardasil 9 Revenue Growth | -19.44% | |||||||||||||||||||||||
Januvia/Janumet Revenue | 574.00M | |||||||||||||||||||||||
Januvia/Janumet Revenue Growth | -27.89% | |||||||||||||||||||||||
ProQuad/M-M-R II/Varivax Revenue | 538.00M | |||||||||||||||||||||||
ProQuad/M-M-R II/Varivax Revenue Growth | -0.19% | |||||||||||||||||||||||
Bridion Revenue | 472.00M | |||||||||||||||||||||||
Bridion Revenue Growth | 7.03% | |||||||||||||||||||||||
Lynparza - Alliance Revenue | 341.00M | |||||||||||||||||||||||
Lynparza - Alliance Revenue Growth | 9.29% | |||||||||||||||||||||||
Winrevair Revenue | 525.00M | |||||||||||||||||||||||
Winrevair Revenue Growth | 87.50% | |||||||||||||||||||||||
Lenvima - Alliance Revenue | 256.00M | |||||||||||||||||||||||
Lenvima - Alliance Revenue Growth | -0.78% | |||||||||||||||||||||||
Pharmaceutical Revenue | 14.35B | |||||||||||||||||||||||
Pharmaceutical Revenue Growth | 5.21% | |||||||||||||||||||||||
Animal Health Revenue | 1.79B | |||||||||||||||||||||||
Animal Health Revenue Growth | 12.78% | |||||||||||||||||||||||
Other Product Revenue | 146.00M | |||||||||||||||||||||||
Other Product Revenue Growth | -51.81% | |||||||||||||||||||||||
Revenue (Other) | -11.81B | |||||||||||||||||||||||
Revenue (Total) | 16.29B | |||||||||||||||||||||||
Revenue (Total) Growth | 4.88% |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 |
United States Revenue | 9.16B | |||||||||||||||||||||||
United States Revenue Growth | 7.53% | |||||||||||||||||||||||
Europe, Middle East and Africa Revenue | 3.89B | |||||||||||||||||||||||
Europe, Middle East and Africa Revenue Growth | 12.51% | |||||||||||||||||||||||
Latin America Revenue | 874.00M | |||||||||||||||||||||||
Latin America Revenue Growth | 10.35% | |||||||||||||||||||||||
China Revenue | 390.00M | |||||||||||||||||||||||
China Revenue Growth | -44.44% | |||||||||||||||||||||||
Asia Pacific (other than China and Japan) Revenue | 738.00M | |||||||||||||||||||||||
Asia Pacific (other than China and Japan) Revenue Growth | 7.11% | |||||||||||||||||||||||
Japan Revenue | 555.00M | |||||||||||||||||||||||
Japan Revenue Growth | -17.04% | |||||||||||||||||||||||
Other Geographic Revenue | 679.00M | |||||||||||||||||||||||
Other Geographic Revenue Growth | -3.14% | |||||||||||||||||||||||
Revenue (Other) | - | |||||||||||||||||||||||
Revenue (Total) | 16.29B | |||||||||||||||||||||||
Revenue (Total) Growth | 4.88% |
EBT
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 |
Pharmaceutical Segment Profit | 11.52B | |||||||||||||||||||||||
Pharmaceutical Segment Profit Growth | 7.53% | |||||||||||||||||||||||
Animal Health Segment Profit | 722.00M | |||||||||||||||||||||||
Animal Health Segment Profit Growth | 13.88% | |||||||||||||||||||||||
Other Segment Profit | 12.24B |